We are live on ! Find out more
AGRX

Agile Therapeutics
AGRX

Delisted

AGRX was delisted on the 25th of March, 2024.

Back to rankings

49 hedge funds and large institutions have $30.5M invested in Agile Therapeutics in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

656% more call options, than puts

Call options by funds: $363K | Put options by funds: $48K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

23% less funds holding

Funds holding: 64 → 49 (-15)

33% less capital invested

Capital invested by funds: $45.7M → $30.5M (-$15.2M)

47% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 19

94% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 16

Holders
49
Holders Change
-15
Holders Change %
-23.44%
% of All Funds
0.86%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
10
Reduced
19
Closed
16
Calls
$363K
Puts
$48K
Net Calls
+$315K
Net Calls Change
-$118K

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$258K
2
GCP
GSA Capital Partners
United Kingdom
+$242K
3
BlackRock
BlackRock
New York
+$183K
4
Northern Trust
Northern Trust
Illinois
+$79.2K
5
SGI
Summit Global Investments
Utah
+$18.1K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$905K
2
Millennium Management
Millennium Management
New York
-$638K
3
TEE
Tibra Equities Europe
United Kingdom
-$321K
4
Goldman Sachs
Goldman Sachs
New York
-$305K
5
Morgan Stanley
Morgan Stanley
New York
-$283K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
51
Goldman Sachs
New York
– -$305K -114 Closed
Jane Street
52
Jane Street
New York
– -$187K -70 Closed
LP
53
LMR Partners
United Kingdom
– -$59K -22 Closed
Two Sigma Advisers
54
Two Sigma Advisers
New York
– -$49K -19 Closed
Charles Schwab
55
Charles Schwab
California
– -$42K -16 Closed
Squarepoint
56
Squarepoint
New York
– -$43K -16 Closed
BFM
57
Boothbay Fund Management
New York
– -$40K -15 Closed
TRCT
58
Tower Research Capital (TRC)
New York
– -$34K -13 Closed
CS
59
Credit Suisse
Switzerland
– -$23K -9 Closed
YIH
60
Y-Intercept (HK)
Hong Kong
– -$24K -9 Closed
AGM
61
Alpine Global Management
New York
– -$18K -7 Closed
Two Sigma Investments
62
Two Sigma Investments
New York
– -$19K -7 Closed
PPA
63
Parametric Portfolio Associates
Washington
– -$17K -6 Closed
RFA
64
Reilly Financial Advisors
California
– -$4K -2 Closed
Northwestern Mutual Wealth Management
65
Northwestern Mutual Wealth Management
Wisconsin
– -$1K -1 Closed
New York State Common Retirement Fund
66
New York State Common Retirement Fund
New York
– -$1K – –
1 2
3

AGRX Hedge Fund Activity: Q3 2021 in Review

49 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q3 2021, worth a combined $30.5M — down 33% from $45.7M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AGRX and 1 opened new positions — a net loss of 15 holders — while 19 trimmed existing stakes and 10 added.

The largest buyer was D.E. Shaw & Co, adding an estimated $258K. The largest seller was Renaissance Technologies, cutting an estimated $905K.

  • 49 institutional investors held Agile Therapeutics (AGRX) as of Q3 2021, down from 64 in Q2 2021.
  • Funds reported $30.5M of Agile Therapeutics stock for Q3 2021, down 33% quarter-over-quarter.
  • 1 fund opened new Agile Therapeutics positions in Q3 2021 and 16 closed out, a net change of -15 holders.
  • The largest Agile Therapeutics buyer in Q3 2021 was D.E. Shaw & Co, an estimated $258K added.
  • The largest Agile Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $905K sold.

Based on aggregated 13F filings for Q3 2021.